Nexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%

MT Newswires Live

2025/10/21

Nexsen (ASX:NXN) started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.

The trial was registered with the Australia and New Zealand Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.

The sensor is designed to provide real time, point of care testing during labor.

Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in Victoria.

Nexsen's shares fell 7% in recent trading on Tuesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577817665"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577817665\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577817665?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 12:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577817665","market":"fut","top_or_hot":-1,"title":"Nexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%","media":"MT Newswires Live","content":"<html><body><p> Nexsen (ASX:NXN) started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.</p><p>The trial was registered with the <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a> Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.</p><p>The sensor is designed to provide real time, point of care testing during labor.</p><p>Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>.</p><p>Nexsen's shares fell 7% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-21 12:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nexsen (ASX:NXN) started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.</p><p>The trial was registered with the <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a> Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.</p><p>The sensor is designed to provide real time, point of care testing during labor.</p><p>Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>.</p><p>Nexsen's shares fell 7% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577817665","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577817665","pubTimestamp":1761020360,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nexsen  started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.The trial was registered with the Australia and New Zealand Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.The sensor is designed to provide real time, point of care testing during labor.Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in Victoria.Nexsen's shares fell 7% in recent trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","XAO.AU":"标普/澳交所 普通股指数","BK7067":"生物科技","NXN.AU":"Nexsen Limited","XKO.AU":"标普/澳交所 300指数"},"translate_title":"Nexsen启动B组链球菌检测装置临床试验；股价下跌7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXN.AU":1,"XKO.AU":0.8,"XAO.AU":0.8,"XJO.AU":0.8},"content_text":"Nexsen (ASX:NXN) started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.The trial was registered with the Australia and New Zealand Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.The sensor is designed to provide real time, point of care testing during labor.Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in Victoria.Nexsen's shares fell 7% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}